Vivos Therapeutics Advances Treatment for Pediatric ADHD
Vivos Therapeutics, Inc. (NASDAQ: VVOS), a pioneer in medical device technology based in Littleton, Colorado, has unveiled compelling clinical data highlighting the effectiveness of its FDA-cleared Daytime-Nighttime Appliance (DNA) in treating children with Attention-Deficit/Hyperactivity Disorder (ADHD) and obstructive sleep apnea (OSA). This breakthrough data proves that Vivos’ innovative approach is offering significant improvements in the quality of life for these children.
Understanding the Unique Challenges
The rise of ADHD diagnoses over the last few decades has been alarming, with the rates reported by the Centers for Disease Control and Prevention (CDC) soaring from around 2%-3% in the 1980s to over 11% in recent years. Similarly, the prevalence of obstructive sleep apnea in children has significantly increased, leading many to connect ADHD symptoms with undiagnosed OSA. This connection is crucial as attention deficits have been observed in up to 95% of pediatric patients diagnosed with OSA.
The Bidirectional Relationship Between ADHD and OSA
The overlap between ADHD and OSA in children presents a unique challenge for both diagnosis and treatment. It can sometimes lead to misdiagnosis, as parents and healthcare professionals may attribute behavioral issues solely to ADHD, overlooking the possibility of underlying sleep disorders. Recent studies indicate strong correlations between OSA severity and the severity of ADHD symptoms, highlighting the need for integrated treatment approaches.
Vivos' Innovative Treatment Mechanism
Vivos’ DNA appliance stands out as a non-surgical and non-pharmaceutical solution, specifically designed for children aged 6 to 17 who are suffering from moderate to severe OSA. As the only FDA 510(k) cleared treatment of its kind for pediatric OSA, it presents a viable alternative to surgical procedures like adenotonsillectomy, which can be daunting for both parents and children involved.
Significant Clinical Outcomes
In the recently published dataset, children treated with the Vivos DNA appliance exhibited a remarkable 50% reduction in Pediatric Sleep Questionnaire (PSQ) scores, which assess various sleep-related issues like snoring and sleep disruption. Consequently, the children also experienced a 58% decrease in symptoms associated with both sleep disordered breathing and ADHD, such as hyperactivity and disruptive behavior.
Positive Impacts on Child Development
The study involved 48 of the initially enrolled 55 patients, comprising a varied cohort of 28 males and 20 females with an average age of 10.6 years. Among these participants, 100% demonstrated significant increases in transpalatal width and airway volume, while their Apnea-Hypopnea Index (AHI) scores indicated a substantial 51.4% decrease in OSA severity. Such improvements not only alleviate immediate symptoms but also foster better behavioral performance and academic success in their daily lives.
Vivos' Commitment to Patient Outcomes
According to Kirk Huntsman, Chairman and CEO of Vivos, the company is uncovering a previously untapped market for effectively addressing ADHD symptoms linked to OSA. Their approach empowers parents who are hesitant to subject their children to invasive surgeries or pharmaceuticals, offering a new ray of hope through safe, effective treatment options. While the Vivos DNA appliance is not specifically FDA-cleared for ADHD, the emerging data strongly supports the notion that alleviating OSA can reduce ADHD symptoms.
About Vivos Therapeutics
Founded in 2016, Vivos Therapeutics, Inc. is at the forefront of developing innovative technologies for managing sleep disorders and breathing-related issues connected to dentofacial abnormalities. Their Complete Airway Repositioning and Expansion (CARE) devices are transforming the treatment landscape for both children and adults suffering from OSA. With a mission to enhance the understanding and treatment of these conditions, Vivos aims to address the root causes of obstructive sleep apnea, rather than merely providing temporary relief.
Transforming Lives with Vivos Method
Vivos promotes a clinically effective and nonsurgical solution known as The Vivos Method, which offers hope for patients seeking to restore their breathing and sleep health. As the company matures, their innovative strategies and devices are positioned to change lives for individuals affected by OSA, allowing them to breathe new life.
Frequently Asked Questions
What is Vivos Therapeutics known for?
Vivos Therapeutics is a medical technology company specializing in the development of innovative solutions for obstructive sleep apnea and related disorders.
How does the Vivos DNA appliance help children with ADHD?
The appliance helps treat obstructive sleep apnea, which can alleviate ADHD symptoms by improving sleep quality and behavior.
What are the reported benefits of the Vivos DNA appliance?
Clinical data shows significant reductions in ADHD symptoms, improved airway volume, and decreased severity of OSA among treated children.
Why is the Vivos DNA appliance considered innovative?
It is the only FDA-cleared non-surgical appliance for treating moderate to severe pediatric OSA, offering a safe alternative to surgery.
Where can I find more information about Vivos?
For additional details about their technology and offerings, please visit www.vivos.com.
